Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Alseres Pharmaceuticals logo — company profile

Alseres Pharmaceuticals

Founded 1972 2-10 employees Post-IPO Equity Total: $4.90M Biotechnology, Health Care +1

General Information

Company Name Alseres Pharmaceuticals
Founded Year 1972
Employees 2-10
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Alseres Pharmaceuticals. To contact Alseres Pharmaceuticals, visit alseres.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Alseres Pharmaceuticals compare?

A PDF of Alseres Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Alseres Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Alseres Pharmaceuticals

Alseres Pharmaceuticals is a biotech company, established in 1972, that is dedicated to developing diagnostic and therapeutic solutions for central nervous system disorders. The company's flagship product, Altropane®, is a pioneering molecular imaging agent designed for diagnosing Parkinson's disease and dementia. Currently, Altropane is in Phase III of clinical development for diagnosing Parkinson's disease. Alseres Pharmaceuticals' strategy for Altropane involves forging partnerships to facilitate the product's further development and eventual commercialization. The company's last investment of $1.00MPost-IPO equity came on 04 November 2009. With a focus on Biotechnology, Health Care, and Health and Wellness industries, Alseres Pharmaceuticals is positioned to address critical unmet needs in CNS disorders diagnosis and treatment.

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $1.00M -
04 Nov 2009
Post IPO Equity $3.90M -
19 Mar 2009

Alseres Pharmaceuticals Alternatives & Competitors

View All Alternatives
Alseres Pharmaceuticals vs
CNS Therapeutics
CNS Therapeutics United States

Delivering advanced neurological and pain treatments with precision and expertise

Venture round
4 employees
Biotechnology, Health Care
Alseres Pharmaceuticals vs
CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. United States

Pre-Clinical Stage Biotech Company Focused on Developing Novel Treatments for Brain Tumors

Post-IPO Equity
9 employees
Biotechnology, Health and Wellness
Alseres Pharmaceuticals vs
AGY Therapeutics
AGY Therapeutics

Pioneering breakthrough treatments for central nervous system diseases through innovative gene disco...

Series C
Biopharma, Biotechnology
View all alternatives

FAQ About Alseres Pharmaceuticals

Alseres Pharmaceuticals, Inc. (ALSE) focuses on creating diagnostic and therapeutic products for central nervous system (CNS) disorders. Our leading product candidate, Altropane®, is a unique molecular imaging agent designed to diagnose Parkinson's disease and dementia. Currently, Altropane is in Ph...
Alseres Pharmaceuticals was founded in 1972.
Alseres Pharmaceuticals operates in Biotechnology, Health Care and Health and Wellness.
Alseres Pharmaceuticals has approximately 2-10 employees.
Alseres Pharmaceuticals has completed 2 funding rounds, raising a total of $4.90M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Alseres Pharmaceuticals include CNS Therapeutics, CNS Pharmaceuticals, Inc., AGY Therapeutics, IRLAB Therapeutics AB, Neurologix. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Alseres Pharmaceuticals and CNS Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Alseres Pharmaceuticals, https://bouncewatch.com/company/alseres-pharmaceuticals, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes